A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

IRB/UVA Tracking #
21337
Contact
Maria Davenport
Contact Email
Contact Phone
1.434.297.4110
Phase
II
Primary purpose
Treatment
Cancer PI
Ryan Gentzler
Status
OPEN TO ACCRUAL
Ages
Adult